klinik retatrutide Lilly's Retatrutide: Toward the End of Incremental Metabolic Medicine Retatrutide

doi: 10.1016/j.bbrc.2019.01.103 49 BomfimTRForny-GermanoLSathlerLBBrito-MoreiraJHouzelJCDeckerHet al

5-12% body weight loss in this range is common for adherent users

Semaglutide was approved as Ozempic in 2017 for type 2 diabetes, then at a higher dose as Wegovy in 2021 specifically for obesity, with clinical trials showing around 15% average body weight loss via slowing how quickly the stomach empties

Missimer A, Dimarco DM, Andersen CJ, Murillo AG, Vergara-Jimenez M, Fernandez ML

Offer it on its own or seamlessly integrated into our daily use personalized health platform

By 2030, the number of GLP-1 users in the US could reach 30 million, representing approximately 9% of the population